Meeting Banner
Abstract #1773

Inter-site repeatability and quantitative assessment of hepatic transporter function with DCE-MRI in rats

Claudia Green1, Sirisha Tadimalla2, Denise Steinmann3, Steven Sourbron2, Sascha Koehler4, Hans-Paul Juretschke3, Iina Laitinen3, John C. Waterton5,6, Paul D. Hockings7,8, Catherine D. G. Hines9, and Gunnar Schuetz1

1MR & CT Contrast Media Research, Bayer AG, Berlin, Germany, 2Leeds Imaging Biomarkers Group, Department of Biomedical Imaging Sciences, University of Leeds, Leeds, United Kingdom, 3R&D TIM - Bioimaging Germany, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany, 4Bruker BioSpin MRI GmbH, Ettlingen, Germany, 5Manchester Science Park, Bioxydyn Ltd, Manchester, United Kingdom, 6Division of Informatics Imaging & Data Sciences, School of Health Sciences, Faculty of Biology Medicine & Health, Centre for Imaging Sciences, Manchester, United Kingdom, 7BioVenture Hub, Antaros Medical, Mölndal, Sweden, 8Chalmers University of Technology, MedTech West, Gothenburg, Sweden, 9Merck & Co., Inc., West Point, PA, United States

Drug-induced liver injury can halt liver-metabolized drug development or cause withdrawal from the market. Toxicologists lack appropriate and reproducible assays. We present repeatability and reproducibility results from a multi-center study with dynamic gadoxetate-enhanced MR imaging biomarkers of hepatic transporter-mediated injury in rats. Our study supports the development of a validated liver function-specific quantitative MR imaging biomarker, and we demonstrate that the biomarkers are repeatable and that the previously reported MR assay findings are reproducible across three centers.

This abstract and the presentation materials are available to members only; a login is required.

Join Here